ClinConnect ClinConnect Logo
Search / Trial NCT00290394

Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

Launched by BASKENT UNIVERSITY · Feb 9, 2006

Trial Information

Current as of July 23, 2025

Completed

Keywords

Blood Pressure, Rosiglitazone,Diabetes Mellitus, Type 2,

ClinConnect Summary

The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks' treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Blood pressure of patients were in normotensive limits according to the JNC VII
  • Diabetes mellitus treated with oral antidiabetics or diet
  • Exclusion Criteria:
  • Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease
  • Anti-hypertensive treatment

About Baskent University

Baskent University is a distinguished academic and research institution dedicated to advancing healthcare through innovative clinical trials and studies. With a strong emphasis on evidence-based medicine, the university collaborates with a network of healthcare professionals and researchers to design and implement rigorous clinical research that aims to improve patient outcomes. Baskent University is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the integrity and reliability of its research initiatives while fostering a collaborative environment that promotes scientific discovery and education.

Locations

Ankara, , Turkey

Patients applied

0 patients applied

Trial Officials

Neslihan B Tutuncu, MD

Study Director

Medical Doctor, Endocrynology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials